Pages that link to "Q37247581"
Jump to navigation
Jump to search
The following pages link to Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (Q37247581):
Displaying 32 items.
- Graft-versus-host disease biomarkers: omics and personalized medicine (Q26824540) (← links)
- Graft-versus-host disease: why have we not made more progress? (Q27012940) (← links)
- A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens (Q33387336) (← links)
- Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease (Q33424311) (← links)
- Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis (Q33643387) (← links)
- A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). (Q33924570) (← links)
- Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. (Q34077792) (← links)
- A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation (Q34272554) (← links)
- Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. (Q34860077) (← links)
- 90Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma (Q35115650) (← links)
- A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients (Q35218515) (← links)
- Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. (Q35231363) (← links)
- Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. (Q35231368) (← links)
- Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis (Q36206849) (← links)
- The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial (Q36734547) (← links)
- Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. (Q36777485) (← links)
- The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate (Q36862464) (← links)
- Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation (Q36868082) (← links)
- Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention (Q36925951) (← links)
- Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat (Q37238884) (← links)
- Progress and prospects: graft-versus-host disease (Q37761297) (← links)
- Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD. (Q37993738) (← links)
- Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis (Q38202155) (← links)
- Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. (Q38212951) (← links)
- The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials (Q38413246) (← links)
- Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation (Q40577820) (← links)
- Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts (Q43846823) (← links)
- GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. (Q48261069) (← links)
- Rapamycin preconditioning attenuates transient focal cerebral ischemia/reperfusion injury in mice (Q48406263) (← links)
- Graft-versus-host disease (Q83468020) (← links)
- Acute Graft-Versus-Host Disease: A Brief Review (Q93050836) (← links)
- Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial (Q93086096) (← links)